CDK4 and colorectal carcinoma: On the one hand, inhibition of CDK4/6 is expected to sensitize CRC to immune checkpoint blockades (ICBs) through upregulation of PD-L1 level32 and reduction of immunosuppressive Treg population.33,34 On the other hand, inhibition of CDK4/6 realized the strong anti-tumor efficacy.